Dr. Falk Nimmerjahn is Professor at the Department of Biology at the Friedrich Alexander University of Erlangen-Nuremberg and is the Director of the Division of Genetics. His research is focused on understanding the pathogenic as well as the therapeutic activity of IgG antibodies. He has a specific interest in understanding autoantibody driven inflammatory pathways in skin and bone tissue, including skin blistering diseases and rheutmatoid arthritis. Another aspect of his research is to decipher how IgG glycosylation affects IgG function and how this knowledge can be used to impair autoantibody activity or to enhance the therapeutic activity of intravenous immunoglobulin G (IgG) therapy.

Dr. Nimmerjahn received his MSc in Biology at the University of Erlangen and his PhD at the Ludwing-Maximilians University of Munich. For his postdoctoral education Dr. Nimmerjahn went to Jeffrey Ravetch at the Rockefeller University in New York where his research focused on understanding the function of Fc-receptors for IgG (FcgRs). Dr. Nimmerjahn received numerous prizes including the Paul Ehrlich Award for young scientists and the award for excellence in science from the European Macrophage and Dendritic Socienty.